The EPS beat and regulatory catalysts (ketamine ANDA decision Q3 2026, NRX-101 IND acceptance) are positive, but the company remains pre-revenue from pharmaceutical sales and operating losses are widening. Monitor the Q3 2026 FDA ANDA decision and the Geneuro asset acquisition closing for the next major catalysts. The $7M ATM raise post-quarter provides runway but dilutes existing holders.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $3.12entry
- T+1 · 6mo ago −2.73%α −2.08% · $3.03
- T+5 · 6mo ago +38.36%α +36.74% · $4.31
- T+20 · 5mo ago +27.45%α +25.87% · $3.97
- T+60 · 3mo ago +7.87%α +3.01% · $3.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.4M from $5.5M a year ago. The company advanced multiple regulatory milestones including an anticipated FDA ANDA decision on preservative-free ketamine in Q3 2026, initiated commercial manufacturing, and generated first revenue from its HOPE Therapeutics clinic network. The beat is notable for a clinical-stage biotech but driven by non-recurring fair value accounting changes rather than operational improvement.
Key Financial Metrics
Key Facts
- EPS -$0.04 vs consensus -$0.13 (69.2% beat)
- Net loss narrowed to $1.4M from $5.5M YoY, though operating loss widened to $4.7M from $3.8M
- Cash and equivalents $6.7M as of March 31, 2026; raised ~$7M post-quarter via ATM
- FDA ANDA decision on preservative-free ketamine expected Q3 2026 with favorable preliminary determinations
- Initiated commercial manufacturing at 1 million dose/month scale; FDA reclassified facility to VAI status
- First revenue generated from five HOPE Therapeutics clinics with VA, DoD, and private insurer funding
- Pending acquisition of Geneuro SA assets (patents, antibodies, Phase 2 data) via Swiss court liquidation
- FDA accepted IND for NRX-101 as adjunct to robotic TMS; non-dilutive federal funding anticipated
Financial Impact
EPS beat of 69.2% on a -$0.13 consensus; net loss improvement of $4.1M YoY; $6.7M cash plus $7M post-quarter ATM proceeds
Risk Factors
- FDA ANDA decision on ketamine could be delayed or result in a Complete Response Letter
- Operating losses are widening ($4.7M vs $3.8M) despite net loss improvement from non-recurring items
- Dilution risk from ongoing ATM facility; $7M raised post-quarter adds to share count
- Clinical-stage biotech with no approved products; revenue from clinics is early-stage and small
- Pending Geneuro acquisition may not close or deliver expected value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296477 |
Track record
22 reports on NRXP
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers